SCHEMBL4577841

SCHEMBL4577841

Cc1ccc(CC2CCN(C(=O)CNc3ccc4[nH]c(=O)oc4c3)CC2)cc1

nearest known ligand 0.62

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
GRIN2D O15399 4/20 0.62
GRIN3B O60391 4/20 0.62
GRIN1 Q05586 4/20 0.62
GRIN2A Q12879 4/20 0.62
GRIN2B Q13224 4/20 0.62
GRIN2C Q14957 4/20 0.62
GRIN3A Q8TCU5 4/20 0.62
CHRNA7 P36544 1/20 0.49
MEN1 O00255 1/20 0.48
LMNA P02545 1/20 0.48
MAPT P10636 1/20 0.48
KMT2A Q03164 1/20 0.48
FAAH O00519 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4420713 0.91 GRIN1 (0.75) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL4411707 0.90 GRIN1 (0.75) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
Hydrochloric Acid SCHEMBL4577994 0.90 GRIN1 (0.74) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL4566679 0.89 GRIN2D (0.59) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL4550674 0.86 GRIN1 (0.83) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL3454623 0.81 GRIN1 (0.60) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL4576956 0.77 GRIN1 (0.84) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL4576995 0.77 GRIN2D (0.60) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
Radiprodil SCHEMBL99256 0.77 GRIN1 (1.00) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL4414151 0.77 GRIN1 (0.83) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7435744-B2 Piperidine derivatives as NMDA receptor antagonists GEDEON RICHTER VEGYESZETI GYAR RT (HU) 2008-10-14 US claimed
EP-1409477-B1 PIPERIDINE DERIVATIVES AS NMDA RECEPTOR ANTAGONISTS RICHTER GEDEON NYRT (HU) 2008-09-17 EP claimed
US-20040157886-A1 Piperdine derivatives as NMDA receptor antagonists UCB Biopharma SRL (BE) 2004-08-12 US claimed
US-7435744-B2 Piperidine derivatives as NMDA receptor antagonists GEDEON RICHTER VEGYESZETI GYAR RT (HU) 2008-10-14 US disclosed
EP-1409477-B1 PIPERIDINE DERIVATIVES AS NMDA RECEPTOR ANTAGONISTS RICHTER GEDEON NYRT (HU) 2008-09-17 EP disclosed
US-20040157886-A1 Piperdine derivatives as NMDA receptor antagonists UCB Biopharma SRL (BE) 2004-08-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040157886-A1 Piperdine derivatives as NMDA receptor antagonists GRIN1, GRIN2D, GRIN2C GRIN2D 2/4885GRIN3B 9/4885GRIN1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.